Fusidic acid - Aceragen
Alternative Names: ACG-701; ARV-1801; ARV-1907; CEM-102; Sodium fusidate; SQ-16603; TakstaLatest Information Update: 26 Feb 2024
At a glance
- Originator Cempra Pharmaceuticals
- Developer Aceragen; Arrevus; Cempra Pharmaceuticals
- Class Anti-infectives; Antibacterials; Cholestadienes; Sterols
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis-associated respiratory tract infections; Melioidosis
- Discontinued Bone and joint infections; Osteomyelitis; Skin and soft tissue infections
Most Recent Events
- 10 Oct 2023 Arrevus in collaboration with Arnasi Group completes a phase II trial in Melioidosis (Combination therapy) in Thailand (PO) (NCT05105035)
- 19 Jul 2023 Aceragen withdrawan a phase II trial due to financial issues associated respiratory tract infections (In adolescents, In adults, In the elderly) for Cystic fibrosis in USA (NCT05641298)
- 13 Mar 2023 Aceragen has patent protection for fusidic acid in US, Japan and Canada prior to March 2023